Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs
Observational
Observational Model: Cohort, Time Perspective: Prospective
Time in weeks to fifty percent decrease in sural nerve action potential amplitude
one year
No
Eugene A Lesser, D.O.
Principal Investigator
NeuroMetrix, Inc.
United States: Food and Drug Administration
99000287
NCT01208545
July 2008
Name | Location |
---|---|
Santa Clara Valley Health and Hospital System | Santa Clara, California 95128 |